This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Biomarker Analysis & Updated Clinical Outcomes - Neoadjuvant Systemic Treatment With Nivolumab and Relatlimab in Surgically Resectable Melanoma"

0 views
July 22, 2024
Comments 0
Login to view comments. Click here to Login